atoltivimabmaftivimabodesivimab sold brand name inmazeb fixeddose combination three monoclonal antibodies treatment zaire ebolavirus ebola contains atoltivimab maftivimab odesivimabebgn developed regeneron common side effects include fever chills tachycardia fast heart rate tachypnea fast breathing vomiting however also common symptoms ebola virus atoltivimabmaftivimabodesivimab first fdaapproved treatment zaire atoltivimabmaftivimabodesivimab approved medical use united states october us food drug administration fda considers firstinclass world health organizations list essential atoltivimabmaftivimabodesivimab indicated treatment infection caused zaire people receive atoltivimabmaftivimabodesivimab avoid concurrent administration live vaccine due treatments potential inhibit replication live vaccine virus indicated prevention ebola virus infection possibly reduce vaccines atoltivimabmaftivimabodesivimab combination zaire ebolavirus glycoproteindirected human monoclonal three antibodies target glycoprotein surface ebola glycoprotein normally attaches cell via receptor fuses viral host cell membranes allowing virus enter antibodies bind simultaneously three different locations block attachment entry combination drug targets zaire species ebola virus sudan bundibugyo strains also caused outbreaks unlikely would effective ebola outbreak killed people regeneron used velocigene velocimmune velocimab antibody discovery production technologies coordinated us governments biomedical advanced research development authority therapy developed six months phase trial healthy humans completed équateur province ebola outbreak similar monoclonal antibody treatment requested democratic republic congo drc ministry public health approved compassionate use world health organization meuri ethical protocol drc ethics board sent along therapeutic agents outbreak however outbreak came conclusion therapeutic agents given approximately one month following conclusion équateur province outbreak distinct outbreak noted kivu drc kivu ebola outbreak received approval compassionate use meuri drc ethic boards given many patients november pamoja tulinde maisha palm together save lives openlabel randomized clinical control trial begun multiple treatment units testing remdesivir zmapp despite difficulty running clinical trial conflict zone investigators enrolled patients towards goal needed second largest outbreak january confirmed probable cases including interim analysis data safety monitoring board dsmb first patient found superior comparator zmapp overall mortality patients zmapp remdesivir groups compared looking patients arrived early disease symptoms appeared survival study powered determine whether difference survival difference two therapies zmapp significant led dsmb halting study palm investigators dropping remdesivir zmapp arms clinical trial patients outbreak elect participate trial given either august congolese health officials announced effective compared two treatments used among patients treated died mortality rate improved drug administered soon infection timely diagnosis critical infected diseases like ebola cause sepsis eventually multiple organ dysfunction syndrome quickly survival rate drug administered shortly infection atoltivimabmaftivimabodesivimab evaluated adult pediatric participants confirmed zaire ebolavirus infection one clinical trial palm trial part expanded access program conducted democratic republic congo drc ebola virus outbreak palm trial safety efficacy atoltivimabmaftivimabodesivimab evaluated multicenter openlabel randomized controlled trial participants received atoltivimabmaftivimabodesivimab mg monoclonal antibody intravenously single infusion participants received investigational trial enrolled pediatric adult participants including pregnant women zaire ebolavirus participants received standard supportive care participants health care providers knew treatment primary efficacy endpoint primary analysis population participants randomized concurrently eligible receive either atoltivimabmaftivimabodesivimab investigational control time period participants received atoltivimabmaftivimabodesivimab died days compared participants received expanded access program additional participants received fda granted application atoltivimabmaftivimabodesivimabebgn orphan drug breakthrough therapy fda granted approval inmazeb regeneron pharmaceuticals indication treatment infection caused zaire ebolavirus october drug also received orphan drug designation european medicines httpsenwikipediaorgwikiatoltivimabmaftivimabodesivimab